Retinal vein occlusions: The potential impact of a dysregulation of the retinal veins

EPMA Journal

Volumn 1, Issue 2, 2010, Pages 253-261

  Fraenkl, Stephan A ^a   Mozaffarieh, Maneli ^a   Flammer, Josef ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

BRVO; Endothelin 1; Personalized treatment; Prevention; Retinal vein occlusion; Vascular dysregulation

Indexed keywords

ENDOTHELIN 1; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANTICOAGULATION; ATHEROSCLEROSIS; BLOOD RETINA BARRIER; BLOOD RHEOLOGY; BLOOD VESSEL PERMEABILITY; CELL PROLIFERATION; CELL SWELLING; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; EYE BLOOD FLOW; GLAUCOMA; HUMAN; HYPOXEMIA; PATHOGENESIS; PRIORITY JOURNAL; RETINA EDEMA; RETINA VEIN; RETINA VEIN OCCLUSION; REVIEW; RISK FACTOR; THROMBOCYTOPENIA; THROMBOGENESIS; UPREGULATION; VEIN THROMBOSIS; VENOCONSTRICTION;

EID: 79953032183     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1007/s13167-010-0025-2     Document Type: Review

References (82)

1. von Leber T. Die Krankheiten der Netzhaut und des Sehnerven. In: Handbuch der gesamten Augenheilkunde. Leipzig: Graefe-Saemisch; 1877. p. 531.
2. Hayreh SS. Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res. 2005; 24: 493-519.
3. Ennema MC, Zeeman WP. Venous occlusions in the retina. Ophthalmologica. 1953; 126: 329-47.
4. Koyanagi Y. Die pathologische Anatomie und Pathogenese des Kreuzungsphänomens der Netzhautgefäße bei Hochdruck. Graefes Arch Clin Exp Ophthalmol. 1935; 135: 526-36.
5. Zhao J, Sastry SM, Sperduto RD, Chew EY, Remaley NA. Arteriovenous crossing patterns in branch retinal vein occlusion. The Eye Disease Case-Control Study Group. Ophthalmology. 1993; 100: 423-8.
6. Duker JS, Brown GC. Anterior location of the crossing artery in branch retinal vein obstruction. Arch Ophthalmol. 1989; 107: 998-1000.
7. Staurenghi G, Lonati C, Aschero M, Orzalesi N. Arteriovenous crossing as a risk factor in branch retinal vein occlusion. Am J Ophthalmol. 1994; 117: 211-3.
8. Weinberg D, Dodwell DG, Fern SA. Anatomy of arteriovenous crossings in branch retinal vein occlusion. Am J Ophthalmol. 1990; 109: 298-302.
9. Christoffersen NL, Larsen M. Pathophysiology and hemodynamics of branch retinal vein occlusion. Ophthalmology. 1999; 106: 2054-62.
10. Klien BA. Prevention of retinal venous occlusion with special reference to ambulatory dicumarol therapy. Am J Ophthalmol. 1950; 33: 175-84. illust.
11. Sperduto RD, Hiller R, Chew E, Seigel D, Blair N, Burton TC, et al. Risk factors for hemiretinal vein occlusion: comparison with risk factors for central and branch retinal vein occlusion: the eye disease case-control study. Ophthalmology. 1998; 105: 765-71.
12. Avci R, Inan UU, Kaderli B. Evaluation of arteriovenous crossing sheathotomy for decompression of branch retinal vein occlusion. Eye. 2008; 22: 120-7.
13. Kube T, Feltgen N, Pache M, Herrmann J, Hansen LL. Angiographic findings in arteriovenous dissection (sheathotomy) for decompression of branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2005; 243: 334-8.
14. Kumagai K, Furukawa M, Ogino N, Uemura A, Larson E. Long-term outcomes of vitrectomy with or without arteriovenous sheathotomy in branch retinal vein occlusion. Retina. 2007; 27: 49-54.
15. Frangieh GT, Green WR, Barraquer-Somers E, Finkelstein D. Histopathologic study of nine branch retinal vein occlusions. Arch Ophthalmol. 1982; 100: 1132-40.
16. Seitz R. The retinal blood vessels. Comparative ophthalmoscopic and histological studies on the healthy and pathologically changed eye. Büch Augenarzt. 1962; 40: 1-175.
17. Rabinowicz IM, Litman S, Michaelson IC. Branch venous thrombosis-a pathological report. Trans Ophthalmol Soc UK. 1969; 88: 191-210.
18. Hayreh SS, Zimmerman MB, Podhajsky P. Hematologic abnormalities associated with various types of retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2002; 240: 180-96.
19. Baglivo E, Dosso A, Pournaras C. Thrombus and branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 1997; 235: 10-3.
20. Jefferies P, Clemett R, Day T. An anatomical study of retinal arteriovenous crossings and their role in the pathogenesis of retinal branch vein occlusions. Aust N Z J Ophthalmol. 1993; 21: 213-7.
21. Greenwood A. Thrombosis of the central retinal vein and its branches. J Am Med Assoc. 1924; 82: 92-100.
22. Koyanagi Y. Veränderungen an der Netzhaut bei Hochdruck. Path Anat 15 Int Kogr Ophthalmol. 1937; 1: 143-283.
23. Kumar B, Yu DY, Morgan WH, Barry CJ, Constable IJ, McAllister IL. The distribution of angioarchitectural changes within the vicinity of the arteriovenous crossing in branch retinal vein occlusion. Ophthalmology. 1998; 105: 424-7.
24. Noma H, Funatsu H, Sakata K, Harino S, Mimura T, Hori S. Macular microcirculation in hypertensive patients with and without branch retinal vein occlusion. Acta Ophthalmol. 2009; 87: 638-42.
25. Messerli J, Flammer J. Central vein thrombosis in younger patients. Klin Monatsbl Augenheilkd. 1996; 208: 303-5.
26. Haufschild T, Prunte C, Messerli J, Flammer J. Increased endothelin-1 plasma level in young adults with retinal vascular occlusive diseases. Klin Monatsbl Augenheilkd. 2004; 221: 357-9.
27. Hollo G. Plasma endothelial-1 concentrations in patients with retinal vein occlusions. Br J Ophthalmol. 1999; 83: 127-8.
28. Iannaccone A, Letizia C, Pazzaglia S, Vingolo EM, Clemente G, Pannarale MR. Plasma endothelin-1 concentrations in patients with retinal vein occlusions. Br J Ophthalmol. 1998; 82: 498-503.
29. Cheung N, Klein R, Wang JJ, Cotch MF, Islam AF, Klein BE, et al. Traditional and novel cardiovascular risk factors for retinal vein occlusion: the multiethnic study of atherosclerosis. Investig Ophthalmol Vis Sci. 2008; 49: 4297-302.
30. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc. 2000; 98: 133-41. discussion 141-133.
31. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol. 1996; 114: 1243-7.
32. Orth DH, Patz A. Retinal branch vein occlusion. Surv Ophthalmol. 1978; 22: 357-76.
33. Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T, et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol. 2005; 140: 256-61.
34. Badala F. The treatment of branch retinal vein occlusion with bevacizumab. Curr Opin Ophthalmol. 2008; 19: 234-8.
35. Hayreh SS, Zimmerman B, McCarthy MJ, Podhajsky P. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol. 2001; 131: 61-77.
36. Browning DJ, Fraser CM. Retinal vein occlusions in patients taking warfarin. Ophthalmology. 2004; 111: 1196-200.
37. Ducos de Lahitte G, Quintyn JC, Leparmentier A, Mathis A. Retinal vein occlusions in patients treated with anticoagulant and/or platelet aggregation inhibitors. Five case studies. J Fr Ophtalmol. 2007; 30: 145-9.
38. Janssen MC, den Heijer M, Cruysberg JR, Wollersheim H, Bredie SJ. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors. Thromb Haemost. 2005; 93: 1021-6.
39. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 1986; 315: 1046-51.
40. Swedberg KB. Impact of neuroendocrine activation on coronary artery disease. Am J Cardiol. 1998; 82: 8H-14H.
41. Pellanda N, Flammer J, Haefliger IO. L-NAME- and U 46619-induced contractions in isolated porcine ciliary arteries versus vortex veins. Klin Monatsbl Augenheilkd. 2001; 218: 366-9.
42. MacCumber MW, Jampel HD, Snyder SH. Ocular effects of the endothelins. Abundant peptides in the eye. Arch Ophthalmol. 1991; 109: 705-9.
43. Connolly DT. Vascular permeability factor: a unique regulator of blood vessel function. J Cell Biochem. 1991; 47: 219-23.
44. Flammer J, Pache M, Resink T. Vasospasm, its role in the pathogenesis of diseases with particular reference to the eye. Prog Retin Eye Res. 2001; 20: 319-49.
45. Teuchner B, Orgul S, Ulmer H, Haufschild T, Flammer J. Reduced thirst in patients with a vasospastic syndrome. Acta Ophthalmol Scand. 2004; 82: 738-40.
46. Takei K, Sato T, Nonoyama T, Miyauchi T, Goto K, Hommura S. A new model of transient complete obstruction of retinal vessels induced by endothelin-1 injection into the posterior vitreous body in rabbits. Graefes Arch Clin Exp Ophthalmol. 1993; 231: 476-81.
47. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett Jr JC. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med. 1991; 325: 997-1001.
48. An SJ, Boyd R, Zhu M, Chapman A, Pimentel DR, Wang HD. NADPH oxidase mediates angiotensin II-induced endothelin-1 expression in vascular adventitial fibroblasts. Cardiovasc Res. 2007; 75: 702-9.
49. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994; 118: 445-50.
50. Kaur C, Foulds WS, Ling EA. Blood-retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management. Prog Retin Eye Res. 2008; 27: 622-47.
51. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res. 2008; 27: 331-71.
52. Faller DV. Endothelial cell responses to hypoxic stress. Clin Exp Pharmacol Physiol. 1999; 26: 74-84.
53. Clemett RS. Retinal branch vein occlusion. Changes at the site of obstruction. Br J Ophthalmol. 1974; 58: 548-54.
54. Orgul S, Kaiser HJ, Flammer J, Gasser P. Systemic blood pressure and capillary blood-cell velocity in glaucoma patients: a preliminary study. Eur J Ophthalmol. 1995; 5: 88-91.
55. Gass A, Flammer J, Linder L, Romerio SC, Gasser P, Haefeli WE. Inverse correlation between endothelin-1-induced peripheral microvascular vasoconstriction and blood pressure in glaucoma patients. Graefes Arch Clin Exp Ophthalmol. 1997; 235: 634-8.
56. Ergul A, Portik-Dobos V, Giulumian AD, Molero MM, Fuchs LC. Stress upregulates arterial matrix metalloproteinase expression and activity via endothelin A receptor activation. Am J Physiol Heart Circ Physiol. 2003; 285: H2225-2232.
57. Stefansson E, Novack RL, Hatchell DL. Vitrectomy prevents retinal hypoxia in branch retinal vein occlusion. Investig Ophthalmol Vis Sci. 1990; 31: 284-9.
58. Sonnsjo B. Similarities between disc haemorrhages and thromboses of the retinal veins. Int Ophthalmol. 1992; 16: 235-8.
59. Tezel G, Wax MB. Hypoxia-inducible factor 1alpha in the glaucomatous retina and optic nerve head. Arch Ophthalmol. 2004; 122: 1348-56.
60. Kaiser HJ, Flammer J, Wenk M, Luscher T. Endothelin-1 plasma levels in normal-tension glaucoma: abnormal response to postural changes. Graefes Arch Clin Exp Ophthalmol. 1995; 233: 484-8.
61. Lip PL, Felmeden DC, Blann AD, Matheou N, Thakur S, Cunliffe IA, et al. Plasma vascular endothelial growth factor, soluble VEGF receptor FLT-1, and von Willebrand factor in glaucoma. Br J Ophthalmol. 2002; 86: 1299-302.
62. Park SP, Ahn JK. Changes of aqueous vascular endothelial growth factor and pigment epithelium-derived factor following intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion. Clin Experiment Ophthalmol. 2009; 37: 490-5.
63. Cumurcu T, Bulut Y, Demir HD, Yenisehirli G. Aqueous humor erythropoietin levels in patients with primary open-angle glaucoma. J Glaucoma. 2007; 16: 645-8.
64. Garci-Arumi J, Fonollosa A, Macia C, Hernandez C, Martinez-Castillo V, Boixadera A, et al. Vitreous levels of erythropoietin in patients with macular oedema secondary to retinal vein occlusions: a comparative study with diabetic macular oedema. Eye. 2009; 23: 1066-71.
65. Rader J, Feuer WJ, Anderson DR. Peripapillary vasoconstriction in the glaucomas and the anterior ischemic optic neuropathies. Am J Ophthalmol. 1994; 117: 72-80.
66. Arend O, Remky A, Plange N, Kaup M, Schwartz B. Fluorescein leakage of the optic disc in glaucomatous optic neuropathy. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle. Ophthalmologie. 2005; 243: 659-64.
67. Grieshaber MC, Flammer J. Does the blood-brain barrier play a role in Glaucoma? Surv Ophthalmol. 2007; 52 Suppl 2: S115-121.
68. Rankin SJ, Drance SM. Peripapillary focal retinal arteriolar narrowing in open angle glaucoma. J Glaucoma. 1996; 5: 22-8.
69. Grieshaber MC, Terhorst T, Flammer J. The pathogenesis of optic disc splinter haemorrhages: a new hypothesis. Acta Ophthalmol Scand. 2006; 84: 62-8.
70. Yoo YC, Park KH. Disc hemorrhages in patients with both normal tension glaucoma and branch retinal vein occlusion in different eyes. Korean J Ophthalmol. 2007; 21: 222-7.
71. Morgan WH, Hazelton ML, Azar SL, House PH, Yu DY, Cringle SJ, et al. Retinal venous pulsation in glaucoma and glaucoma suspects. Ophthalmology. 2004; 111: 1489-94.
72. Jonas JB. Ophthalmodynamometric assessment of the central retinal vein collapse pressure in eyes with retinal vein stasis or occlusion. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle. Ophthalmologie. 2003; 241: 367-70.
73. Flammer J, Haefliger IO, Orgul S, Resink T. Vascular dysregulation: a principal risk factor for glaucomatous damage? J Glaucoma. 1999; 8: 212-9.
74. Leroux Les Jardins G, Glacet-Bernard A, Lasry S, Housset B, Coscas G, Soubrane G. Retinal vein occlusion and obstructive sleep apnea syndrome. J Fr Ophtalmol. 2009; 32: 420-4.
75. Mojon DS, Hess CW, Goldblum D, Fleischhauer J, Koerner F, Bassetti C, et al. High prevalence of glaucoma in patients with sleep apnea syndrome. Ophthalmology. 1999; 106: 1009-12.
76. Prasanna G, Hulet C, Desai D, Krishnamoorthy RR, Narayan S, Brun AM, et al. Effect of elevated intraocular pressure on endothelin-1 in a rat model of glaucoma. Pharmacol Res. 2005; 51: 41-50.
77. Saarelainen S, Seppala E, Laasonen K, Hasan J. Circulating endothelin-1 in obstructive sleep apnea. Endothelium. 1997; 5: 115-8.
78. Weiss JW, Liu MD, Huang J. Physiological basis for a causal relationship of obstructive sleep apnoea to hypertension. Exp Physiol. 2007; 92: 21-6.
79. Gasser P, Flammer J, Guthauser U, Mahler F. Do vasospasms provoke ocular diseases? Angiology. 1990; 41: 213-20.
80. Gugleta K, Zawinka C, Rickenbacher I, Kochkorov A, Katamay R, Flammer J, et al. Analysis of retinal vasodilation after flicker light stimulation in relation to vasospastic propensity. Investig Ophthalmol Vis Sci. 2006; 47: 4034-41.
81. Mozaffarieh M, Schoetzau A, Sauter M, Grieshaber M, Orgul S, Golubnitschaja O, et al. Comet assay analysis of single-stranded DNA breaks in circulating leukocytes of glaucoma patients. Mol Vis. 2008; 14: 1584-8.
82. Koseki N, Araie M, Tomidokoro A, Nagahara M, Hasegawa T, Tamaki Y, et al. A placebo-controlled 3-year study of a calcium blocker on visual field and ocular circulation in glaucoma with low-normal pressure. Ophthalmology. 2008; 115: 2049-57.